Verifying…
Home / Drug A–Z / Tazocin 4EF Injection

Tazocin 4EF Injection

NAFDAC Reg. No. A4-9951 · Drug

Registered with NAFDAC. Registration activeAs of 27 October 2026 · synced automatically from official sources.
Product
Tazocin 4EF Injection
NAFDAC number
A4-9951
Active ingredient
Piperacillin (Piperacillin Sodium); Tazobactam (Tazobactam Sodium)
Strength
4 g; 500 mg
Form
Powder for injection
Pack size
1 x 12's (in 70 mL Type I glass vials)
Manufacturer
Not listed
Applicant (holder)
Pfizer Specialties Ltd
Approved
24 Jun 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
23 Jun 2026
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Tazocin 4EF Injection is on the NAFDAC register with an active registration (A4-9951). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Tazocin 4EF Injection is used for

From the official U.S. FDA label for piperacillin (piperacillin sodium), the active ingredient registered with NAFDAC.

What it is used for

Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and tazobactam and other antibacterial drugs, piperacillin and tazobact …

Possible side effects

The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Adverse Reactions [see Warnings and Precautions (5.1) ] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.2) ] Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5.3) ] Rhabdomyolysis [see Warnings and Precautions (5.4) ] Hematologic Adverse Reactions [see Warnings and Precautions (5.5) ] Central Nervous System Adverse Reactions [see Warnings and Precautions (5.6) ] Nephrotoxicity in Critically Ill Patients [see Warnings and Precautions (5.7) ] Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions (5.9) ] The most common adver …

Do not use if

Piperacillin and tazobactam is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or beta-lactamase inhibitors. Patients with a history of allergic reactions to any of the penicillins, cephalosporins, or beta-lactamase inhibitors. ( 4 )

Warnings

Serious hypersensitivity reactions (anaphylactic/anaphylactoid) reactions have been reported in patients receiving piperacillin and tazobactam. Discontinue piperacillin and tazobactam if a reaction occurs. ( 5.1 ) Piperacillin and tazobactam may cause severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis. Discontinue Piperacillin and tazobactam for progressive rashes. ( 5.2 ) Hemophagocytic lymphohistiocytosis (HLH) has been reported with the use of Piperacillin and tazobactam. …

Pregnancy & breastfeeding

IN SPECIFIC POPULATIONS Dosage in patients with renal impairment (creatinine clearance ≤40 mL/min) should be reduced based on the degree of renal impairment. ( 2.3 , 8.6 ) 8.1 Pregnancy Risk Summary Piperacillin and tazobactam cross the placenta in humans. However, there are insufficient data with piperacillin and/or tazobactam in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. …

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Tazocin 4EF Injection

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Tazocin 4EF Injection

What is in Tazocin 4EF Injection?

Tazocin 4EF Injection contains Piperacillin (Piperacillin Sodium); Tazobactam (Tazobactam Sodium) (4 g; 500 mg), as powder for injection, according to its NAFDAC registration record.

Is Tazocin 4EF Injection registered with NAFDAC?

Yes. Tazocin 4EF Injection is listed on the NAFDAC register under registration number A4-9951, and its registration is active as of 27 October 2026.

Has Tazocin 4EF Injection been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Tazocin 4EF Injection in our automatically synced alert list.

How can I check that my pack of Tazocin 4EF Injection is genuine?

Run a free authenticity scan with the NAFDAC number A4-9951, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Tazocin 4EF Injection used for?

Piperacillin and tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin (Summarised from the official U.S. FDA label for piperacillin (piperacillin sodium). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Tazocin 4EF Injection? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.